Angiogenic factors in diabetic ocular disease: Mechanisms of today, therapies for tomorrow

International Ophthalmology Clinics

Volumn 38, Issue 2, 1998, Pages 89-102

  Robinson, Gregory S ^a   Aiello, Lloyd Paul ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACIDIC FIBROBLAST GROWTH FACTOR; ADENOSINE; ANGIOGENESIS INHIBITOR; ANGIOGENIN; ANGIOPOIETIN 1; ANGIOPOIETIN 2; BASIC FIBROBLAST GROWTH FACTOR; EPIDERMAL GROWTH FACTOR; FIBRIN; GROWTH FACTOR; GROWTH HORMONE; INTEGRIN; PLASMINOGEN ACTIVATOR; SOMATOMEDIN C; TRANSFORMING GROWTH FACTOR ALPHA; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANGIOGENESIS; DIABETES MELLITUS; DIABETIC RETINOPATHY; DRUG MECHANISM; GROWTH REGULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOMODULATION; IMMUNOPATHOGENESIS; NEOVASCULARIZATION (PATHOLOGY); PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW;

EID: 0031867565     PISSN: 00208167     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004397-199803820-00007     Document Type: Review

References (87)

1. Norrby K. Angiogenesis: new aspects relating to its initiation and control. APMIS 1997;105:417-437
2. Folkman J. How is blood vessel growth regulated in normal and neoplastic tissue? G.H.A. Clowes Memorial Award Lecture. Cancer Res 1986;46:467-473
3. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971;285:1182-1186
4. Mahlotra R, Stenn KS, Fernandez LA, Braverman IM. Angiogenic properties of normal and psoriatic skin associated with epidermis, not dermis. Lab Invest 1989;61:162-165
5. Klein HA, Moorehead HB. Statistics on blindness in the model reporting area, 1969-1970. (DHEW pub. no. [NIH] 73-427, 1970.) Bethesda, MD: US Department of Health, Education and Welfare, 1973
6. Klein R, Klein BEK. Vision disorders in diabetes. In: National Diabetes Data Group. Diabetes in America: Diabetes Data Compiled 1984. (NIH publ. no. 85-1468). Bethesda, MD: US Department of Health and Human Services 1985:1-2
7. Javitt JC, Aiello LP, Bassi LJ, et al. Detecting and treating retinopathy in patients with type 1 diabetes mellitus. Ophthalmology 1991;98:1565-1574
8. Javitt JC, Aiello LP, Chiang YP, et al. Preventive eye care in people with diabetes is cost saving to the federal government. Diabetes Care 1994;17:909-917
9. Klein R, et al. The Wisconsin Epidemiologic Study of Diabetic Retinopathy: XV. The long-term incidence of macular edema. Ophthalmology 1995;102:7-16
10. Javitt JC, Canner JK, Sommer A. Cost effectiveness of current approaches to the control of retinopathy in Type 1 diabetics. Ophthalmology 1989;96:255-264
11. Klein R, Klein BE, Moss SE, et al. The Wisconsin Epidemiologic Study of Diabetic Retinopathy: II. Prevalence and risk of diabetic retinopathy when age at diagnosis is less than 30 years. Arch Ophthalmol 1984;102:520-526
12. Diabetic Retinopathy Study Group Photocoagulation of proliferative diabetic retinopathy [Diabetic Retinopathy Study rep No. 2. Ophthalmology 1978;85:82
13. Early Treatment Diabetic Retinopathy Study Group. Early photocoagulation for diabetic retinopathy [ETDRS rep. no. 9]. Ophthalmology 1991;98:766-785
14. Michaelson IC. The mode of development of the vascular system of the retina, with some observations on its significance for certain retinal disease. Trans Ophthalmol Soc UK 1998;68:137-180
15. Ashton N. Retinal vascularization in health and disease. Am J Ophthalmol 1957;44:7-24
16. Battegay EJ. Angiogenesis: mechanistic insights, neovascular diseases, and therapeutic prospects. Mol Med 1995;73:333-346
17. Burgess WH, Maciag T. The heparin binding (fibroblast) growth factor family of proteins. Ann Rev Biochem 1989;58:575-606
18. Vlodavsky I, Folkman J, Sullivan R, et al. Endothelial cell-derived basic fibroblast growth factor: synthesis and deposition into subendothelial extracellular matrix. Proc Natl Acad Sci USA 1987;84(8):2292-2296
19. Gao H, Hollyfield JG. Basic fibroblast growth factor (bFGF) immunolocalization in the rodent outer retina demonstrated with an anti-rodent bFGF antibody. Brain Res 1992;585:355-360
20. Montesano R, Vassali JD, Baird A, et al. Basic fibroblast growth factor induces angiogenesis in vitro. Proc Natl Acad Sci USA 1986;83:7297-7301
21. Shing Y, Folkman J, Haudenschild C, et al. Angiogenesis is stimulated by a tumor-derived endothelial cell growth factor. J Cell Biochem 1985;29:275-287
22. Abraham JA, Mergia A, Whang JL, et al. Nucleotide sequence of a bovine clone encoding the angiogenic protein, basic fibroblast a growth factor. Science 1986;233:545-548
23. Kandel J, Bossy-Wetzel E, Radvany F, et al. Neovascularization is associated with a switch to the export of bFGF in the multistep development of fibrosarcoma. Cell 1991;66: 1095-1104
24. McNeil PL, Muthukrishman L, Warder E, D'Amore PA. Growth factors are released by mechanically wounded endothelial cells. J Cell Biol 1989;109(2):811-822
25. Sivalingam A, Kenney J, Brown GC, et al. Basic fibroblast growth factor levels in the vitreous of patients with proliferative diabetic retinopathy. Arch Ophthalmol 1990;108:869-872
26. Pepper M, Ferrara N, Orci L, Montesano R. Potent synergism between vascular endothelial growth factor and basic fibroblast growth factor in the induction of angiogenesis in vitro. Biochem Biophys Res Comm 1992;189:824-831
27. Senger DR, Galli SJ, Dvorak AM. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 1983;219:983-985
28. Keck PJ, Hauser SD, Krivi G. Vascular permeability factor, an endothelial cell mitogen related to PDGF. Science 1989;246:1309-1312
29. Leung DW, Cachianes G, Kunang WJ. Vascular Permeability factor is a secreted angiogenic mitogen. Science 1989;246:1306-1309
30. Aiello LP, Bursell SE, Clermont A, et al. Vascular endothelial growth factor-induced retinal permeability is mediated by protein kinase C in vivo and suppressed by an orally effective Beta isoform-selective inhibitor. Diabetes 1997;46:1473-1480
31. Thieme H, Aiello LP, Takagi H, et al. Comparative analysis of vascular endothelial growth factor (VEGF) receptors on retinal and aortic microvascular endothelial cells. Diabetes 1994;44:98-103
32. Aiello LP, Northrup JM, Keyt BA, et al. Hypoxic regulation of vascular endothelial growth factor in retinal cells. Arch Ophthalmol 1995;113(12):1538-1544
33. Aiello LP, Pierce EA, Foley ED, et al. Inhibition of vascular endothelial growth factor suppresses retinal neovascularization in vivo. Proc Natl Acad Sci USA 1995;92(23):10457-10461
34. Robinson GS, Pierce EA, Rook SL, et al. Oligodeoxynucleotides inhibit retinal neovascularization in a murine model of proliferative retinopathy. Proc Natl Acad Sci USA 1996; 93:4851-4856
35. Adamis A, et al. Inhibition of VEGF prevent ocular neovascularization in a non-human primate. Arch Ophthalmol 1996;114:66-71
36. Aiello LP, Avery RL, Arrigg OG, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal diseases. N Engl J Med 1994;331: 1480-1487
37. Lutty GA, McLeod DS, Merges C, et al. Localization of VEGF in human retina and choroid. Arch Ophthalmol 1996;114:971-977
38. Amin RH, Frank RN, Kennedy A, et al. Vascular endothelial growth factor is present in glial cells of the retina and optic nerve of human subjects with nonproliferative diabetic retinopathy. Invest Ophthalmol Vis Sci 1997;38:36-47
39. Clermont A, Aiello LP, Mori F, et al. Vascular endothelial growth factor (VEGF) and severity of nonproliferative diabetic retinopathy (NPDR) mediate retinal hemodynamics in vivo: A potential role for VEGF in the progression of nonproliferative diabetic retinopathy. Am J Ophthalmol 1997;124:433-446
40. Vinores SA, Kuchle M, Mahlow J, et al. Blood-ocular barrier breakdown in eyes with ocular melanoma. A potential role for vascular endothelial growth factor/vascular permeability factor. Am J Pathol 1995;147:1289-1297
41. Lopez PF, Sippy BD, Lambert HM, et al. Transdifferentiated retinal pigment epithelial cells are immunoreactive for vascular endothelial growth factor in surgically excised age-related macular degeneration-related choroidal neovascular membranes. Invest Opthalmol Vis Sci 1996;37:855-868
42. Pu X, Aiello LP, Jiang ZY, et al. Characterization of vascular endothelial growth factor's effect on the activation of phospholipase Cγ protein kinase C pathways and endothelial cell growth. J Clin Invest 1996;98:2018-326
43. Ishii H, et al. Amelioration of vascular dysfunction in diabetic rats by an oral PKC β inhibitor. Science 1996;272:728-731
44. Poulsen JE. The houssay phenomenon in man: recovery from retinopathy in a case of diabetes with Simmonds' disease. Diabetes 1958;2:7-12
45. Poulsen JE. Diabetes and anterior pituitary insufficiency: final course and postmortem study of a diabetic patient with Sheehan's syndrome. Diabetes 1966;15:73-77
46. Zimmerman BR, Molnar GD. Prolonged follow-up in diabetic retinopathy treated by sectioning the pituitary stalk. Mayo Clin Proc 1977;52:233-237
47. Merimee TJ. Metabolic and clinical studies in growth hormone deficient dwarfs: a ten year follow-up. N Engl J Med 1978;298:1217-1222
48. Passa R, Rousselie F, Gauville C, Canivet J. Retinopathy and plasma growth hormone levels in idiopathic hemochromatosis with diabetes. Diabetes 1977;26:113-120
49. Sundkvist G, Almer L, Pandolfi M. Growth hormone and endothelial function during exercise in diabetics with and without retinopathy. Acta Med Scand 1984;215:55-61
50. Merimee TJ, Zapf J, Groesch ER. Insulin-like growth factors: studies in diabetics with and with retinopathy. N Engl J Med 1983;309:527-530
51. Dills DG, Moss SE, Klein R, Klein BE. Association of elevated IGF-1 levels with increased retinopathy in late-onset diabetes. Diabetes 1991;40:1724-1730
52. Grant MB, Russel B, Fitgerald C, Merimee TJ. Insulin-like growth factors in vitreous: studies in controls and diabetics with neovascularization. Diabetes 1986;35:416-420
53. Wang Q, Dills DG, Klein R, et al. Does insulin-like growth factor 1 predict incidence and progression of diabetic retinopathy. Diabetes 1995;44:161-164
54. Grant MB, Guay C, Marsh R. Insulin-like growth factor I stimulates prolifertion, migration, and plasminogen activator release by human retinal pigment epithelial cells. Curr Eye Res 1990;9:323-335
55. Grant MB, Mames RN, Fitgerals C, et al. Insulin-like growth factor I as an antiangiogenic agent: in vivo and vitro studies. Ann NY Acad Sci 1993;692:230-242
56. Smith LEH, Kopchick JJ, Chen W, et al. Essential role of growth hormone in ischemia-induced retinal neovascularization. Science 1997;276:1706-1709
57. Hynes RO. Integrins: versality, modulation and signaling in cell adhesion. Cell 1992;69: 11-25
58. Juliano RL, Haskill S. Signal transduction from the extracellular matrix. J Cell Biol 1993; 120:577-585
59. Ruoslahti E. Integrins. J Clin Invest 1991;87:1-5
60. Luscinskas FW, Lawler J. Integrins as dynamic regulators of vascular function. FASEB J 1996;8:929-938
61. Schwartz MA, Schaller MD, Ginsberg MH. Integrins: emerging paradigms of signal transduction. Annu Rev Cell Dev Biol 1995;11:549-599
62. vβ5 in angiogenesis. In: Goldberg ID, Rosen EM, eds. Regulation of angiogenesis. Basel: Birkhauser Verlag, 1997:361-390
63. Cheresh D. Integrins: structure, function and biological properties. Adv Mol Cell Biol 1993;6:225-252
64. Miyamoto S, Teramoto H, Coso OA, et al. Integrin function: molecular hierarchies of cytoskeletal and signaling molecules. J Cell Biol 1995;131:791-805
65. Sastry SK, Horwitz A. Integrin cytoplasmic domains: mediators of cytoskeletal linkages and extra- and intracellular initiated transmembrane signaling. Curr Opin Cell Biol 1993;5:819-832
66. Brooks PC. Role of integrins in angiogenesis. Eur J Cancer 1996;14:2423-2429
67. Polverini PJ. Cellular adhesion molecules: newly identified mediators of angiogenesis. Am J Pathol 1996;148:1023-1029
68. Enenstein J, Walesh NS, Kramer RH. Basic FGF and TGF-β differential modulate integrin expression of human microvascular endothelial cells. Exp Cell Res 1992;203:499-503
69. Swerlick RA, Brown EJ, Xu Y, et al. Expression and modulation of vitronectin receptor on human dermal microvascular endothelial cells. J Invest Dermatol 1992;99:715-722
70. Drake CJ, Davis LA, Little CD. Antibodies to β1-integrins cause alterations of aortic vascularization in vivo. Dev Dyn 1991;193:83-91
71. 3, prevents maturation of blood vessels during embryonic neovascularization. J Cell Sci 1995;108:2655-2661
72. Hynes RO, Bader BL. Targeted mutations in integrins and their ligands: their implications for vascular biology. Thromb Haemost 1997;78:83-87
73. Hynes RO. Targeted mutations in cell adhesion genes: what have we learned from them? Dev Biol 1996;180:40-412
74. Erenstein J, Kramer RH. Confocal microscope analysis of integrin expression on the microvascular and its sprouts in the neonatal foreskin. J Invest Dermatol 1994;103:381-386
75. 3 for angiogenesis. Science 1994;264:569-571
76. 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell 1994;79:1157-1164
77. v integrins. Science 1995;270:1500-1502
78. Hammes H-P, Brownlee M, Jonczyk A, et al. Subcutaneous injection of a cyclic peptide antagonist of vitronectin receptor-type integrins inhibits retinal neovascularization. Nature Med 1996;5:529-533
79. Friedlander M, Theesfeld CL, Sugita M, et al. Involvement of integrins alpha v beta 3 and alpha v beta 5 in ocular neovascular diseases. Proc Natl Acad Sci USA 1996;93: 9764-9769
80. Sato TN, Tozawa Y, Deutsch U, et al. Distinct roles of the receptor tyrosine kinases Tie-1 and Tie-2 in blood vessel formation. Nature 1995;376:70-74
81. Sato TN, Qin Y, Kozak CA, Audus KL. Tie-1 and Tie-2 define another class of putative receptor tyrosine kinase genes expressed in early embryonic vascular system. Proc Natl Acad Sci USA 1993;90:9355-9358
82. Schnurch H, Risau W. Expression of Tie-2, a member of a novel family of receptor tyrosine kinases, in the endothelial cell lineage. Development 1993;119:957-968
83. Korhonen J, Polvi A, Partanen J, and Alitalo K. The mouse tie receptor tyrosine kinase gene: expression during embryonic angiogenesis. Oncogene 1994;9:395-403
84. Suri C, Jones PF, Patan S, et al. Requisite role of Angiopoietin-1, a ligand for the TIE-2 receptor, during embryonic angiogenesis. Cell 1996;87:1171-1180
85. Maisonpierre PC, Suri C, Jones PJ, et al. Angiopoietin-2, a natural antagonist for Tie-2 that disrupts in vivo angiogenesis. Science 1997;277:55-60
86. Hanahan D. Signaling vascular morphogenesis and maintenance. Science 1997;277: 48-50
87. D'Amato RJ, Luoghnan MS, Flynn E, Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 1994;91:4082-4085